Suppr超能文献

产前皮质类固醇暴露与 22 至 23 周龄婴儿存活率的关系。

Association of Antenatal Corticosteroid Exposure and Infant Survival at 22 and 23 Weeks.

机构信息

Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Center for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

出版信息

Am J Perinatol. 2023 Dec;40(16):1789-1797. doi: 10.1055/s-0041-1740062. Epub 2021 Nov 28.

Abstract

OBJECTIVE

In 2014, the leading obstetric societies published an executive summary of a joint workshop to establish obstetric interventions to be considered for periviable births. Antenatal corticosteroid administration between 22 and 22 weeks was not recommended given existing evidence. We sought to evaluate whether antenatal steroid exposure was associated with improved survival among resuscitated newborns delivered between 22 and 23 weeks of gestation.

STUDY DESIGN

We conducted a population-based cohort study of all resuscitated livebirths delivered between 22 and 23 weeks of gestation in the United States during 2009 to 2014 utilizing National Center for Health Statistics data. The primary outcome was rate of survival to 1 year of life (YOL) between infant cohorts based on antenatal steroid exposure. Multivariable logistic regression estimated the association of antenatal steroid exposure on survival outcomes.

RESULTS

In the United States between 2009 and 2014, there were 2,635 and 7,992 infants who received postnatal resuscitation after delivery between 22 to 22 and 23 to 23 weeks of gestation, respectively. Few infants born at 22 (15.9%) and 23 (26.0%) weeks of gestation received antenatal corticosteroids (ANCS). Among resuscitated neonates, survival to 1 YOL was 45.2 versus 27.8% (adjusted relative risk [aRR]: 1.6, 95% confidence interval [CI]: 1.2-2.1) and 57.9 versus 47.7% (aRR: 1.3, 95% CI: 1.1-1.5) for infants exposed to ANCS compared with those not exposed at 22 and 23 weeks of gestation, respectively. When stratified by 100 g birth weight category, ANCS were associated with survival among neonates weighing 500 to 599 g (aRR: 1.9, 95% CI: 1.3-2.9) and 600 to 699 g (aRR: 1.7, 95% CI: 1.1-2.6) at 22 weeks.

CONCLUSION

Exposure to ANCS was associated with higher survival rates to 1 YOL among resuscitated infants born at 22 and 23 weeks. National guidelines recommending against ANCS utilization at 22 weeks should be re-evaluated given emerging evidence of benefit.

KEY POINTS

· Exposure to antenatal steroids was associated with higher survival rates at 22 and 23 weeks of gestation.. · Women exposed to antenatal steroids were more likely to have an adverse outcome.. · The association between steroids and survival was observed among infants with birth weights > 500 g..

摘要

目的

2014 年,主要的产科协会发表了一份联合研讨会的执行摘要,旨在确定考虑用于极早产儿的产科干预措施。鉴于现有证据,不建议在 22 至 22 周之间给予产前皮质类固醇治疗。我们试图评估在 22 至 23 孕周分娩的复苏新生儿中,产前皮质激素暴露是否与存活率提高有关。

研究设计

我们利用美国国家卫生统计中心的数据,对 2009 年至 2014 年间在美国分娩的所有在 22 至 23 孕周接受复苏的活产儿进行了一项基于人群的队列研究。主要结局是根据产前皮质激素暴露情况,比较婴儿队列在 1 年生命(YOL)期间的存活率。多变量逻辑回归估计了产前皮质激素暴露对生存结果的关联。

结果

在美国,2009 年至 2014 年间,分别有 2635 名和 7992 名在 22 周至 22 周和 23 周至 23 周之间分娩后接受了产后复苏的婴儿。很少有在 22 周(15.9%)和 23 周(26.0%)分娩的婴儿接受产前皮质激素治疗(ANCS)。在接受复苏的新生儿中,1 岁时的存活率为 45.2%比 27.8%(调整后的相对风险[aRR]:1.6,95%置信区间[CI]:1.2-2.1)和 57.9%比 47.7%(aRR:1.3,95% CI:1.1-1.5),分别为暴露于 ANCS 的婴儿与未暴露于 22 周和 23 周的婴儿相比。当按 100g 出生体重分类时,ANCS 与体重 500 至 599g(aRR:1.9,95% CI:1.3-2.9)和 600 至 699g(aRR:1.7,95% CI:1.1-2.6)的新生儿的存活率相关在 22 周。

结论

在 22 周和 23 周出生的接受复苏的婴儿中,暴露于产前皮质激素与较高的 1 岁生存率相关。鉴于新兴的益处证据,应重新评估建议在 22 周时不使用产前皮质类固醇的国家指南。

重点

·产前皮质激素的暴露与 22 周和 23 周的妊娠生存率更高有关。·暴露于产前皮质激素的女性更有可能出现不良结局。·皮质激素与存活率之间的关联在出生体重>500g 的婴儿中观察到。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验